Eye Catching Active Stocks: TE Connectivity Ltd. (NYSE:TEL), Biogen Inc. (NASDAQ:BIIB)

TE Connectivity Ltd. (NYSE:TEL) [Trend Analysis] try to make new thrust in street and making different trends, stocks trading ended with 0.20% to $70.60. The TE Connectivity Ltd. (TEL) Board of Directors authorized a recommendation to increase the company’s quarterly dividend from $0.37 to $0.40 per share, for the four fiscal quarters starting in April 2017, the beginning of the third fiscal quarter.

The recommendation would raise the company’s dividend from the annual rate of $1.48 per share to $1.60 per share, and will be presented for shareholder approval at the company’s Annual General Meeting of Shareholders on March 8, 2017. The recommendation represents the seventh consecutive year of increases to the company’s annual dividend rate. The share price of TEL attracts active investors, as stock price of week volatility recorded 1.73%. The stock is going forward to its 52-week low with 39.80% and lagging behind from its 52-week high price with 0.07%.

Biogen Inc. (NASDAQ:BIIB) [Trend Analysis] attempts to attain leading position in street, Shares price changes as it 1.49% to close at $289.54 with the total traded volume of 4.77 Million shares. Biogen (BIIB) reported that it will present new data from the Phase 1b (PRIME) study of aducanumab, its investigational treatment for early Alzheimer’s disease (AD), at the 9th Clinical Trials on Alzheimer’s Disease (CTAD) meeting in San Diego.Data presentations include interim results from the titration cohort of the placebo-controlled period of the Phase 1b study as well as data from the first year of the long-term extension (LTE).

The results support the ongoing Phase 3 studies of aducanumab for early AD.“The data at CTAD support the positive results we have seen in our Phase 1b study of aducanumab, and they provide insight into the observed effects in patients treated for up to two years,” said Samantha Budd Haeberlein, vice president, clinical development at Biogen. “We are committed to advancing our global Phase 3 program for aducanumab as well as the scientific understanding of Alzheimer’s disease so we can help identify a treatment for the many people affected by this terrible disease.” The firm has institutional ownership of 88.30%, while insider ownership included 0.10%. Its price to sales ratio ended at 5.55. BIIB attains analyst recommendation of 2.00 with week performance of -2.11%.

 

About Blake Escott

Blake Escott holds junior writer position in SWR. Before joining Streetwise Report, he was a freelance content Writer. He has high-level copywriting experience and particularly experienced in proofreading and editing. He covers news about different companies including all US market sectors. Interests: Commodities, Energy stocks, Sector-wise Stocks analysis, Utilities

Leave a Reply

Your email address will not be published. Required fields are marked *